Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
- 25 February 2009
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 157 (4), 606-612
- https://doi.org/10.1016/j.ahj.2008.12.014
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive ImpairmentJAMA, 2008
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Expression of Concern ReaffirmedNew England Journal of Medicine, 2006
- Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000;343:1520-8.New England Journal of Medicine, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThe Lancet, 2004
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid ArthritisJAMA, 1999